# DESCRIPTION

## TECHNICAL FIELD OF THE INVENTION

- relate to virus purification method

## BACKGROUND OF THE INVENTION

- motivate HCV vaccine development

## SUMMARY OF THE INVENTION

- introduce purification method

## DETAILED DESCRIPTION OF THE INVENTION

### Definitions

- define clarification
- define ultrafiltration
- define chromatography
- define SXC
- define SCMA
- define dynamic binding capacity
- define virus particles
- define isolate and strain
- define sequence identity
- define composition
- define elution buffer
- describe SCMA
- outline method of purifying whole virus particles
- describe inactivation and nuclease treatment
- specify virus particles
- describe cell culture
- outline pharmaceutical compositions and use of purified virus particles
- provide additional information and references

### EXAMPLES

- introduce Huh7.5 cell culture
- describe HCV production and infectivity titres
- outline serial passage for high-titre genotype La HCV
- detail sequence analysis of HCV populations
- evaluate infectious HCV stability at alkaline pH values
- describe virus clarification, ultrafiltration, and inactivation
- outline nuclease treatment and chromatographic purification
- determine dynamic binding capacities for SXC and SCMA
- quantify HCV, protein, and DNA in chromatographic samples
- describe ultracentrifugation-based downstream process
- introduce HCV purification
- test alkaline SXC conditions
- determine dynamic binding capacity
- study effect of nuclease treatment on SXC
- polish SXC elution using SCMA chromatography
- apply DSP to different HCV genotypes
- compare chromatography-based DSP to ultracentrifugation-based DSP
- summarize protein and DNA depletion
- conclude advantages of chromatography-based DSP

